Phase I Study of Bortezomib (Velcade) and Cetuximab (Erbitux) for Patients With Solid Tumors Expressing EGFR [epithelial growth factor receptor]
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Bortezomib (Primary) ; Cetuximab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 16 Apr 2010 Actual end date (1 Feb 2010) added as reported by ClinicalTrials.gov record.
- 16 Apr 2010 Actual number of patients (37) added as reported by ClinicalTrials.gov record.